Abstract

The Novel corona virus was first reported in Wuhan province of China in the late 2019. It outspread rapidly which led to a new health crisis throughout the world by the beginning of March 2020 and was considered as a global epidemic. Several deteriorating health symptoms, morbidity and mortality were reported globally by WHO, with more than 34 lakh deaths being reported by 26 May 2021. Presently 16 vaccines are approved under emergency use in different countries and more than 33 vaccines are under phase 3 clinical trials and nearly 130 vaccines are in development phase. By the end of 2020 several new variants in U.K, South Africa, Brazil and India were reported which caused the second wave of COVID-19, for which new trials of vaccine are running to evaluate the efficacy and safety. Several technical problems are associated regarding the production, storing and supplying of these vaccines. For controlling the epidemic, the major challenge is to produce billions of vaccines and to make it available to the underdeveloped and poorer nations. This extensive review provides the details of the different variants of corona viruses reported in the different regions of the world, current vaccines approved under emergency use which are being administered throughout the globe, on-going and listed clinical trials on different vaccines under study for possible use in Covid-19 virus and future challenges associated with Covid-19 scenario.

Highlights

  • Coronaviruses (CoVs) allied with substantial disease epidemics in East Asia and the Middle East which later spread to Europe

  • Bharat Biotech India BBV154 intranasal vaccine is under phase I clinical trial, Adcovid intranasal vaccine is under phase 2 trial by Altimmune company of Maryland, and Ad5-based oral SARS-CoV-2 tablets are designed by Vaxart is in phase 1 clinical trial are in progress [101,102]

  • New variants of COVID-19 had been a major challenge on the vaccine effectiveness, as some of the recent variants like B.1.617.2 of India reported to spread 50% more than the conventional COVID-19 virus

Read more

Summary

Introduction

Coronaviruses (CoVs) allied with substantial disease epidemics in East Asia and the Middle East which later spread to Europe. In a study performed in U.K, the Pfizer vaccine two dose had shown effectiveness of 88 % against Indian variant B.1.617.2 and 93% against the U.K variant B.1.1.7, the vaccine has shown effectiveness against the New York B.1.526 and California B.1.429 variants too [50,78,79,80] It is a one-shot recombinant vector containing SARSCOV-2 virus spike protein sequence and is indicated to be used to develop the immunogenic response in the age group 18 years or older individuals. In a report of phase 3 trial participants of 18-84 years were given Novavax vaccine dose of 5 μg each 3 weeks apart, conferred 89.3 % protection against Covid-19 prototype and demonstrated the increased efficacy up to 85.6 % against the UK Variant B.1.1.7 [86,87].

Discussion
Findings
Conclusion
54. AstraZeneca’s COVID-19 vaccine
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call